tiprankstipranks
Trending News
More News >

Kissei Pharmaceutical Launches YSELTY in Europe

Kissei Pharmaceutical Launches YSELTY in Europe

Kissei Pharmaceutical Co (JP:4547) has released an update.

Confident Investing Starts Here:

Kissei Pharmaceutical Co. has announced the first commercial sale in Germany of YSELTY, a new treatment for uterine fibroids developed and licensed out to Theramex. YSELTY is a GnRH receptor antagonist that has been approved in Europe for use with or without Add-back therapy, offering an alternative for patients unable to take hormonal agents. The financial impact of this launch has been factored into Kissei’s consolidated earnings forecast for the fiscal year ending March 2025.

For further insights into JP:4547 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App